SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
3 Biotechs That Could be Taken Out This Quarter
Business
Biogen Spinoff Bioverativ Takes Out Bay Area’s True North in $825 Million Deal
May 23, 2017
 · 
3 min read
Pharm Country
Why Long-Term Investors Should Prefer Celgene Over Biogen
May 22, 2017
 · 
1 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Business
Biogen’s CSO Quietly Leaves, But Will Still Get R&D Funding From the Biotech Giant
May 15, 2017
 · 
3 min read
How Biogen Makes Most of Its Cash
Job Trends
More R&D Fat is Trimmed as Biogen Closes Doors on UK’s Convergence Pharma
May 12, 2017
 · 
2 min read
3 Biotechs That Could be Taken Out This Quarter
Business
Biogen Exec Leaves to Put Together and Helm New Biotech Startup
May 11, 2017
 · 
3 min read
Business
How Genentech Could Be A New Threat For Biogen
May 10, 2017
 · 
1 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Business
Biogen’s Ex-CEO George Scangos Left a Very Wealthy Man
April 27, 2017
 · 
2 min read
Business
Biogen Earnings: New Drug Sparks Life
April 27, 2017
 · 
1 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
Some Predict Biogen’s Alzheimer’s Drug Will Fail
April 26, 2017
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
December 23, 2025
 · 
13 min read
Press Releases
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS
December 11, 2025
 · 
6 min read
Press Releases
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
December 10, 2025
 · 
8 min read
Press Releases
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 9, 2025
 · 
11 min read
Press Releases
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
December 4, 2025
 · 
24 min read
Press Releases
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 3, 2025
 · 
21 min read
Press Releases
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Press Releases
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Load More